Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmunity. It uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. It has a pipeline of both clinical and preclinical-stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB); VTP-200 for the treatment of human papilloma virus infection (HPV); VTP-850 for the treatment of prostate cancer; VTP-600 for the treatment of non-small cell lung cancer (NSCLC); VTP-1000 for the treatment of celiac disease, and VTP-1100 for the treatment of HPV-associated cancers. Its prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles, and VTP-500 for the prevention of Middle East respiratory syndrome (MERS).
ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees
|May 12, 2023|
|April 17, 2023|
|March 28, 2023|
|March 24, 2023|
|March 20, 2023|
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.
Copyright © 2023. All rights reserved.